Monitor Akebia's stock price closely for any recovery above $1.00. The company has until April 19, 2027, to cure the deficiency, and a reverse stock split is a likely remedy. Traders should watch for any announcements regarding a reverse split or capital raise, as these could create near-term volatility. If the stock fails to recover, delisting would likely lead to further downside.
Price Chart
Executive Summary
Akebia Therapeutics received a Nasdaq deficiency notice on October 21, 2026, because its common stock bid price closed below $1.00 for 30 consecutive business days, violating the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company has 180 calendar days (until April 19, 2027) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, and it may pursue a reverse stock split if needed. Failure to cure could lead to delisting, which would severely reduce institutional ownership and liquidity.
Key Facts
- Nasdaq deficiency notice received October 21, 2026 for bid price below $1.00 for 30 consecutive business days.
- Initial 180-day compliance period ends April 19, 2027.
- To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.
- Company may seek a reverse stock split if necessary to cure the deficiency.
- If not cured, a second 180-day compliance period may be available, but delisting risk remains if compliance is not achieved.
- Market cap is approximately $162 million.
- 83% of analysts rate the stock as Buy or Strong Buy.
Financial Impact
Delisting risk with potential loss of Nasdaq listing; no specific dollar amounts provided in the filing.
Risk Factors
- Failure to regain compliance within the initial or second compliance period could result in delisting from Nasdaq.
- Reverse stock split, if implemented, may be viewed negatively by the market and could lead to further price declines.
- Continued low stock price may trigger additional institutional selling and reduced liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001517022-26-000075 |
| Document: 0001517022-26-000075-index-headers.html | 0001517022-26-000075 |
| Document: 0001517022-26-000075-index.html | 0001517022-26-000075 |
| Document: 0001517022-26-000075.txt | 0001517022-26-000075 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $0.6438 $0.6604 | ▲ +2.58% | ▲ +2.02% | $0.6440 (+0.03%) |
Oct 23, 2026 4d ago | 8-K | $0.6438 $0.6604 | ▼ −2.58% | ▼ −2.02% | $0.6440 (−0.03%) |
Oct 14, 2026 13d ago | 8-K | $0.7020 $0.6955 | ▼ −0.93% | ▼ −1.21% | $0.6440 (−8.26%) |
Sep 22, 2026 5w ago | Institutional Cluster | $0.9800 $0.9326 | ▼ −4.84% | ▼ −4.12% | $0.6440 (−34.29%) |
Jun 30, 2026 17w ago | 8-K | $1.14 $1.21 | ▲ +6.14% | ▲ +6.28% | $0.6440 (−43.51%) |
Apr 30, 2026 25w ago | Press Release | $1.40 | awaiting T+1 | — | $0.6440 (−54.00%) |
Feb 26, 2026 34w ago | 8-K | $1.32 $1.31 | ▼ −0.76% | ▼ −0.30% | $0.6440 (−51.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers